Amendments have been proposed to change the Controlled Substances Act (CSA) for hemp and hemp-derived compounds by the U.S. Drug Enforcement Administration (DEA).
The changes proposed will modify how different cannabinoids and products produced from them are classified to get them closer in line with the laws laid out in the 2018 Farm Bill. The statement includes following changes.
- It modifies 21 CFR 1308.11(d)(31) by adding language stating that the definition of “Tetrahydrocannabinols” does not include “any material, compound, mixture, or preparation that falls within the definition of hemp set forth in 7 U.S.C. 1639 o.”
- It removes from control in schedule V under 21 CFR 1308.15(f) a “drug product in finished dosage formulation that has been approved by the U.S. Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1% (w/w) residual tetrahydrocannabinols.”
- It also removes the import and export controls described in 21 CFR 1312.30(b) over those same substances.
- It modifies 21 CFR 1308.11(d)(58) by stating that the definition of “Marihuana Extract” is limited to extracts “containing greater than 0.3 percent delta-9-tetrahydrocannabinol on a dry weight basis.”
The changes in the rules are there to make the DEA’s regulations mirror what is already in place by the CSA. The DEA isn’t looking to add any requirements to the regulations. The administration will be taking public comments on the amendments until October 20, 2020.